Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by BNP Paribas Financial Markets

BNP Paribas Financial Markets boosted its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 448.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,294 shares of the company’s stock after purchasing an additional 16,597 shares during the quarter. BNP Paribas Financial Markets’ holdings in Protagonist Therapeutics were worth $913,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its position in Protagonist Therapeutics by 749.2% during the 3rd quarter. GAMMA Investing LLC now owns 552 shares of the company’s stock worth $25,000 after acquiring an additional 487 shares during the period. Exchange Traded Concepts LLC acquired a new position in Protagonist Therapeutics during the 3rd quarter worth $43,000. CWM LLC boosted its position in Protagonist Therapeutics by 910.3% during the 3rd quarter. CWM LLC now owns 1,273 shares of the company’s stock worth $57,000 after acquiring an additional 1,147 shares during the period. Harvest Fund Management Co. Ltd acquired a new position in Protagonist Therapeutics during the 3rd quarter worth $69,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Protagonist Therapeutics by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,130 shares of the company’s stock worth $95,000 after acquiring an additional 379 shares during the period. Institutional investors and hedge funds own 98.63% of the company’s stock.

Insiders Place Their Bets

In other Protagonist Therapeutics news, insider Arturo Md Molina sold 26,000 shares of the company’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $44.70, for a total value of $1,162,200.00. Following the completion of the transaction, the insider now owns 46,444 shares of the company’s stock, valued at $2,076,046.80. This represents a 35.89 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Dinesh V. Ph D. Patel sold 78,520 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $46.96, for a total value of $3,687,299.20. Following the completion of the sale, the chief executive officer now directly owns 435,208 shares of the company’s stock, valued at approximately $20,437,367.68. The trade was a 15.28 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 209,863 shares of company stock valued at $9,689,847 in the last 90 days. 5.40% of the stock is currently owned by insiders.

Protagonist Therapeutics Price Performance

NASDAQ:PTGX opened at $41.00 on Thursday. The business’s 50-day simple moving average is $44.53 and its 200-day simple moving average is $40.40. Protagonist Therapeutics, Inc. has a fifty-two week low of $19.00 and a fifty-two week high of $48.89. The stock has a market capitalization of $2.44 billion, a PE ratio of 15.41 and a beta of 2.18.

Analyst Ratings Changes

A number of analysts have recently commented on PTGX shares. Wedbush reissued an “outperform” rating and issued a $58.00 price objective on shares of Protagonist Therapeutics in a research note on Tuesday, November 19th. The Goldman Sachs Group started coverage on Protagonist Therapeutics in a research note on Friday, December 6th. They issued a “neutral” rating and a $47.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Protagonist Therapeutics in a research note on Tuesday. TD Cowen raised Protagonist Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 25th. Finally, BMO Capital Markets initiated coverage on Protagonist Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $62.00 price target on the stock. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Protagonist Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $53.78.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.